Hostname: page-component-f554764f5-68cz6 Total loading time: 0 Render date: 2025-04-15T09:24:56.396Z Has data issue: false hasContentIssue false
  • English
  • Français

The clinical significance of drug-placebo differences

Published online by Cambridge University Press:  23 November 2017

I. Kirsch Open the ORCID record for I. Kirsch [Opens in a new window]
I. Kirsch*
Affiliation:
Program in Placebo Studies, Harvard Medical School, Boston, USA
*
Address for correspondence: I. Kirsch, Program in Placebo Studies, Harvard Medical School, Boston, USA. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Adverse effectsantidepressantsdepressiondepressionpsychotropic drugs
Type
Commentary to Special Article
Information
Epidemiology and Psychiatric Sciences , Volume 27 , Issue 3 , June 2018 , pp. 240 - 241
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Cohen, J (1988). Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates: Hillsdale, NJ.Google Scholar
Dworkin, RH, Turk, DC, Farrar, JT, Haythornthwaite, JA, Jensen, MP, Katz, NP, Witter, J (2005). Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113, 9–19.Google Scholar
Farrar, JT, Young, JP Jr., LaMoreaux, L, Werth, JL, Poole, RM (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94, 149–158.Google Scholar
Jakobsen, JC, Katakam, KK, Schou, A, Hellmuth, SG, Stallknecht, SE, Leth-Møller, K, Gluud, C (2017). Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 17, 58.Google Scholar
Leucht, S, Hierl, S, Kissling, W, Dold, M, Davis, JM (2012). Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. British Journal of Psychiatry 200, 97–106.Google Scholar
Leucht, S, Fennema, H, Engel, R, Kaspers-Janssen, M, Lepping, P, Szegedi, A (2013). What does the HAMD mean? Journal of Affective Disorders 148, 243–248.Google Scholar
Leucht, S, Helfer, B, Gartlehner, G, Davis, JM (2015). How effective are common medications: a perspective based on meta-analyses of major drugs. BMC Medicine 13, 253.Google Scholar
Moncrieff, J, Kirsch, I (2015). Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemporary Clinical Trials 43, 60–62.Google Scholar
NICE (2004). Depression: Management of depression in primary and secondary care. Clinical practice guideline No 23. Retrieved from http://www.nice.org.uk/page.aspx?o=235213.Google Scholar